Hepatitis C: Boehringer Ingelheim's faldaprevir granted accelerated assessment from European Medicines Agency

27-11-2013 Business Wire HealthComments (0)

Antibiotics and Infectious diseasesBoehringer IngelheimfaldaprevirPharmaceutical

EMA grants faldaprevir accelerated assessment for the treatment of hepatitis C. The application is based on a comprehensive clinical development programme including STARTVerso data from AASLD

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top